NewTimeSpace News:On March 13, 2026, Singapore-incorporated Abundance International issued an announcement, stating that it has completed the incorporation of its wholly-owned subsidiary ASC, and ASC has signed a licence agreement dated March 13 with MTTI of the United States.

The announcement indicated that ASC has a registered capital of S$50,000, with funds sourced from Abundance's internal resources. Its core business includes the distribution and trading of chemicals and related products, as well as research and experimental development in the fields of chemistry, medical and veterinary sciences.

Pursuant to the licence agreement, ASC has obtained the exclusive licence for CypH-11 in selected Asia-Pacific countries, entitling it to conduct the research and development as well as commercialisation of the product. It is reported that CypH-11 is a tumour detection agent capable of identifying viable tumour cells, which can be formulated into a sprayable specialty chemical solution. The solution is used in surgical procedures to distinguish cancerous tissue from healthy tissue in real time under near-infrared illumination, helping to reduce the risk of cancer recurrence. The research, development and commercialisation of this product are subject to regulatory approvals and clinical trial clearances in the relevant jurisdictions.

The announcement specified that ASC is required to pay an upfront licence fee of US$125,000 upon the signing of the agreement, and a further US$125,000 after MTTI completes the transfer of all relevant licences and patents for CypH-11 to ASC. Subsequent payments will be made in instalments based on the progress of clinical trials, the number of sublicences granted, and the proceeds from commercialisation.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.